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Background:  Severe  respiratory  syncytial  virus  (RSV)  disease  occurs  predominantly  in children  under
6 months  of age.  There  is  no licensed  RSV  vaccine.  Protection  of young  infants  could  be  achieved  by
a  maternal  vaccine  to boost  titres  of  passively  transferred  protective  antibodies.  Data  on  the  level  and
kinetics  of functional  RSV-speciﬁc  antibody  at birth  and  over  the  early  infant  period  would  inform  vaccine
product  design.
Methods: From  a  birth  cohort  study  (2002–2007)  in  Kiliﬁ,  Kenya,  100  participants  were  randomly  selected
for  whom  cord  blood  and  2 subsequent  3-monthly  blood  samples  within  the  ﬁrst  year  of  life, were
available.  RSV antibodies  against  the A2  strain  of RSV  were  assayed  and  recorded  as  the  logarithm  (base
2)  plaque  reduction  neutralisation  test  (PRNT)  titre.  Analysis  by  linear  regression  accounted  for  within-
person  clustering.
Results:  The  geometric  mean  neutralisation  antibody  titre  was  10.6  (SD:  1.13)  at  birth  with  a  log-linear
decay  over  the  ﬁrst  6 months  of  life.  The  estimated  rate  of  decay  was  −0.58  (SD:  0.20)  log2PRNT  titre per
month  and a  half-life  of  36 days.  There  was  no signiﬁcant  interaction  between  cord  titre  and  rate  of  decay
with  age.  Mean  cord  titres  rose  and  fell  in a pattern  temporally  tracking  community  virus transmission.
Conclusions:  In this  study  population,  RSV  neutralising  antibody  titres  decay  approximately  two-fold
every  one  month.  The  rate  of decay  varies  widely  by  individual  but  is  not  related  to  titre  at  birth.  RSV
speciﬁc  cord  titres  vary  seasonally,  presumably  due  to maternal  boosting.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
Severe RSV disease occurs primarily in infancy and predomi-
nantly among children 1–5 months of age [1]. Globally, RSV disease
may  be responsible for nearly 200,000 deaths per year in young
children and 99% of these deaths occur in low income countries [2].
An annual rate of hospitalisation with RSV associated pneumonia
of 1–2 per 100 for children in the ﬁrst year of life has been reported
in a rural community in Coastal Kenya [1,3].
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Prevention of RSV disease is primarily targeted towards young
infants [4], for which two  vaccine strategies are appropriate: ﬁrst,
to vaccinate infants at the earliest age when able to develop a pro-
tective immune response with minimal reactogenicity, and second,
to boost the level of RSV-speciﬁc antibodies in pregnant women
before delivery to extend the duration of protective antibodies in
early infancy [5–7].
There is evidence which supports the idea that maternal speciﬁc
RSV antibodies provide protection from RSV disease [7,8]. Glezen
et al. demonstrated that infants born with higher levels of antibody
develop infection at a later age, and infants infected in the pres-
ence of moderate levels of serum antibody have milder illnesses
than infants infected with lower or undetectable levels of antibody
[7]. A case-control study in rural Mozambique showed that high
levels of antibodies of maternal origin were associated with pro-
tection against RSV disease [5]. A randomised double blind placebo
controlled trial among premature infants and infants with bron-
chopulmonary dysplasia showed that monthly prophylaxis with
http://dx.doi.org/10.1016/j.vaccine.2015.02.039
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Palivizumab (a humanised monoclonal IgG antibody) was associ-
ated with a 55% reduction in hospitalisation as a result of RSV [9]. In
addition, there are data that suggest a deﬁned level of neutralising
antibody which protects against RSV disease [10].
The success of a maternal RSV vaccination strategy will be
governed by the degree to which a vaccine will boost levels of pro-
tective antibodies transferred by the mother to the infant and by
the rate at which those antibodies decay. In this study we provide
baseline data necessary to evaluate vaccine potential. Speciﬁcally,
in a birth cohort of infants from Kiliﬁ in Kenya, we  estimate the
mean of and variation in RSV neutralising (i.e. functional) antibody
in newborn cord blood, and its rate of decay in relation to starting
titre.
2. Methods
2.1. Study site and population
This study was conducted at the Kenya Medical Research Insti-
tute (KEMRI)—Wellcome Trust Collaborative Research Programme,
in Kiliﬁ, coastal Kenya [11]. Between 1999 and 2007, a birth cohort
study [12,13] was  conducted to investigate susceptibility to inva-
sive pneumococcal disease among children aged 0 to 23 months.
This study was a natural history study, with no intervention, in
which cord and 3 monthly blood samples were collected for each
participant.
The current study used archived serum samples of children who
were participants of the Kiliﬁ Birth Cohort (KBC) study and who
were residents of the Kiliﬁ Health and Demographic Surveillance
System (KHDSS). Characteristics of this study population have been
described before [11,12,14].
Approximately 6000 KBC study participants were recruited in
the maternity ward and at the maternal and child health clinic at
Kiliﬁ District Hospital (KDH). A random sample of 100 participants
from the KBC study, recruited from the KDH maternity ward, were
selected from the study database regardless of RSV disease. Each
selected participant had at least 3 blood samples (speciﬁcally, a cord
blood and two follow up samples) each separated by approximately
3 months.
The temporal pattern of cases of RSV associated severe pneumo-
nia was derived from continuous surveillance of children under 5
years of age admitted to Kiliﬁ District Hospital, Kiliﬁ, which serves
the KHDSS population [1,15]. An RSV epidemic was  empirically
deﬁned to begin when at least 10% of tested samples were RSV pos-
itive or with the observation of at least 2 cases of RSV infection per
week in each of 2 consecutive weeks and were deﬁned to continue
as long as these conditions were satisﬁed, with the requirement
that an epidemic must last for ≥4 weeks as previously deﬁned [1].
These data were used to compare with the temporal pattern of cord
titres.
The Kenya National Ethical Review Committee approved this
study.
2.2. Laboratory procedures
Archived serum samples had been stored at −80 ◦C. The titre
of RSV neutralising antibodies was determined by a plaque
reduction neutralisation test (PRNT) as described previously [16].
The method incorporated a step in which serum samples were
incubated at 56 ◦C in a water bath for 30 min  to inactivate com-
plement cascade proteins. The dilution of a test serum sample
required to induce 50% neutralisation of a known titration of
RSV A2 virus was determined using the Spearman Karber method
[16].
2.3. Statistical analyses
Data analysis was  conducted using STATA version 11.2 (College
Station, Texas). The laboratory data were merged with archived
data from the KBC and KHDSS databases for analysis. Sample PRNT
titres were logarithmically transformed (base 2) for all statistical
analyses. The titre of cord, ﬁrst and second samples for an individ-
ual were deﬁned as TC, T1 and T2, respectively. To offset bias on the
rate of decay arising from RSV infection, we applied the following
criteria. For individuals with T1 ≥ TC, all results for that individual
were excluded, and for individuals with T2 ≥ T1 the result for sam-
ple T2 was excluded. In addition, all samples collected at ages ≥7 m
after birth were excluded due to there being few in number and of
wide age range (7–11 m)  and a high likelihood that the measured
antibody would be active rather than passive. The rate of decay of
RSV speciﬁc log2PRNT titres from birth to <7 months of life was
determined by simple linear regression, accounting for clustering
of titres for samples from the same individual using the procedure
for Huber–White sandwich estimator. Possible interaction between
cord antibody titre and rate of decay of maternal antibodies was
tested using the model with individuals categorised by quartile of
titre at birth. Age dependence in the rate of decay of antibody titres
was evaluated by comparing model ﬁts using linear and quadratic
terms for age. The Wald test was used to evaluate the signiﬁcance
of removal of variables in nested models. To evaluate the effect of
infection on the antibody levels, the rate of decay of those partic-
ipants with at least 2 samples collected within an RSV epidemic
was estimated and compared to that of participants with at least
2 samples collected outside an RSV epidemic. A two  sample t-test
was used to compare the levels of neutralising antibodies and the
mean of the rates of decay between samples collected within and
outside an RSV epidemic and between binary covariates for birth-
weight (low birth weight <2.5 kg) measured using a weighing scale
at birth and gestation period (premature < 37 weeks) based on date
of last menstruation or by clinical evaluation.
3. Results
A total of 300 samples from 100 cohort participants were
selected. For 8 individuals, the second follow-up sample (T2) was
not available, therefore, 292 samples were screened for RSV spe-
ciﬁc neutralising antibodies. Applying the exclusion criteria as
described in the Methods, 18 additional samples were removed (9
samples with T2 ≥ T1 and 9 samples ≥7 months), leaving 274 sam-
ples from 100 participants (76 with 3 samples, 22 with 2 samples
and 2 with 1 sample) for analysis.
The frequency distribution of log-transformed PRNT titres for
cord blood samples was approximately normal (Fig. 1) with mean
concentration 10.6 (95% Conﬁdence Interval (CI) 10.3–10.7, vari-
ance 1.28) and median of 10.6 (Interquartile Range (IQR) 9.95–11.4,
10th percentile 8.87 log2PRNT). The mean birth weight in kilograms
of the participants in this study was 2.89 kg (SD: 0.49) and 19% were
born with low birthweight <2.5 kg (mean: 2.16; SD: 0.21). Only 63
participants had data on gestational period. The mean gestation
period in weeks was  38.6 (SD: 3.16). Of the 63 individuals with
gestational data, 15(24%) were born prematurely i.e. <37weeks
(mean 34.4; SD: 2.48). There was a signiﬁcant difference in the cord
blood neutralising antibody concentrations among the low birth
weight, 9.9 log2PRNT compared to the normal weight 10.7log2PRNT
(P = 0.02, t = −2.37) and between premature, 9.8 log2PRNT and not
premature, 10.9 log2PRNT (P = 0.002, t = −3.18).
The distribution of log-transformed PRNT titres by age is shown
in Fig. 2, with the best ﬁt linear regression model (age range 0–<7 m)
giving an average reduction per month in log2PRNTof −0.58 (95%CI:
−0.65 and −0.51), and a predicted mean titre at birth of 10.5 (95%CI
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Fig. 1. Frequency distribution of maternally transferred RSV speciﬁc antibodies
(log2 transformed PRNT titres) at birth for 100 infants born in Kiliﬁ, Kenya. The
overall mean (variance) and upper and lower quartile titres (log2PRNT) are shown.
10.2 and 10.7). The estimated rate of decay for participants for
whom all samples were collected within an RSV epidemic (n = 48;
Samples = 98) was −0.56 log2PRNT per month (95%CI: −0.66 and
−0.46) while those whose samples were all collected outside an
RSV epidemic (n = 31; Samples = 66) was −0.67 log2PRNT per month
(95%CI: −0.81 and −0.53). The difference in the rates of decay
between those within an RSV epidemic and outside an epidemic
was not statistically signiﬁcant (P = 0.19, t = −1.32). The estimated
rate of decay for samples collected in children under 4 m of age was
−0.64 log2PRNT per month (95%CI: −0.70 and −0.58). We explored
possible age-dependence in the rate of decay of antibody titre by ﬁt-
ting a quadratic term for age in the regression model. The estimate
had a signiﬁcant result (Wald test P = 0.001) and was  not consid-
ered further, since the plots for the two models appeared similar
with a predicted starting titre of 10.5 log2PRNT. The different rates
of decay with their corresponding half life and mean duration are
detailed in Table 1.
Results of regression analysis of the rate of decay of RSV anti-
bodies by age and by quartile at birth (i.e. cord titre) is also shown
in Fig. 2. There was no evidence that slope varied by quartile, i.e. no
evidence of an interaction (Wald test comparing models with age
and cord titre with or without interaction, P = 0.70.).
The distribution of individual rates of decay of RSV PRNT titres
(shown in Fig. 3) is unimodal with mean −0.58 (i.e. half life of
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Fig. 2. The decay in PRNT titre (log base 2 transformed) over the ﬁrst 6 months
of  life for a birth cohort, Kiliﬁ, Kenya, with best ﬁt linear decay model for all sam-
ples (mean) and for each quartile cord level (q1–q4) assuming a ﬁxed rate of decay
(−0.58 log2PRNT titre per month).
Table 1
The rate of decay, mean duration and Half-life for different categories of infants in
a  Kiliﬁ Birth Cohort.
Category Rate of decay
(log2PRNT/month)
Mean duration
in days
Half-life in
days
Overall −0.58 52 36
Within epidemic −0.56 54 37
Outside epidemic −0.67 45 31
<4months −0.64 47 32
>4months −0.51 59 41
Std dev.= 0.20
Percentile 25% 0.44, 75% 0.68
Mean=0.58
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Fig. 3. A histogram of the distribution of individual rates of decay showing the
overall mean (standard deviation; inter-quartile range), −log2PRNT/month.
36 days), variance 0.04, and IQR −0.44–0.68, i.e. 25% of the sample
had a half life of maternal antibodies of ≥48 ≤31 days.
Analysis of covariates on the rate of decay showed no statisti-
cally signiﬁcant effect on underweight <2.5 kg vs normal weight
>2.5 kg (log2PRNT per month −0.62 vs −0.57; P = 0.32) and pre-
mature birth vs full term (log2PRNT per month −0.66 vs −0.55;
P = 0.06).
Further analysis of the cord neutralisation titres by distribut-
ing them against date of collection and overlaying with weekly
RSV cases admitted to Kiliﬁ District Hospital is shown in Fig. 4.
The results suggest that children born at the end and ﬁrst quar-
ter after an RSV epidemic have higher titres of RSV neutralising
Fig. 4. Dynamics of cord titres by time and transmission intensity. Grey symbols
denote individual cord titres by date of birth, black square markers the mean cord
titre by quarter (95% CI), and the vertical bars show the number of RSV IFAT positive
paediatric severe or very severe pneumonia admissions to Kiliﬁ District Hospital
2002–2008.
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antibodies 10.8 log2PRNT (SD: 1.06) relative to children born mid
inter-epidemic and at the early stage of the epidemic10.0 log2PRNT
(SD: 1.01) (P = 0.043, t = −2.09).
4. Discussion
RSV is a major cause of severe respiratory disease among infants
under 6 months of age [1]. Studies have found that infants born
with high levels of RSV speciﬁc maternal antibodies are afforded
a degree of protection against the development of severe RSV
associated pneumonia during the ﬁrst months of life when the risk
of severe disease is greatest [8,17]. Hence, maternal vaccination
to boost protective speciﬁc antibodies in early infancy represents
a plausible disease prevention strategy for RSV. A number of
maternal vaccines based on the RSV F protein are now under-
development [18] (http://www.clinicaltrials.gov/ct2/show/study/
NCT01905215). This study was undertaken to deﬁne the baseline
characteristics of maternal RSV neutralising antibody transfer
and duration in support of the maternal vaccination intervention
strategy (http://sites.path.org/vaccinedevelopment/respiratory-
syncytial-virus-rsv/vaccine-development/).
In a low income predominantly rural population we  estimated
a mean concentration of cord neutralising antibody level of 10.6
log2PRNT. These results are slightly lower compared to those found
in a recent study conducted in Bangladesh [19]. However, other
studies reported neutralising antibody titres lower than our esti-
mates [20,21]. We  also found that, the cord antibody level is related
to birthweight and gestational period; which are some of the fac-
tors reported to inﬂuence transplacental antibody transfer [22].
This indicates that infants born prior to 28 weeks are less likely
to gain antibody levels since RSV speciﬁc antibodies do not readily
cross the placenta before the 28th week of gestation.
We  identiﬁed the rate of decay to be −0.58 log2PRNT per month
in the ﬁrst 6 months of life, indicating a half life of 36 days. Since
the rate of decay might be affected by RSV transmission we  com-
pared rates for individuals whose samples were collected within
or outside of RSV epidemic periods and found a faster rate of
decay (−0.67 log2PRNT per month; half-life 31 d) for the latter,
though the difference was not statistically signiﬁcant. However,
we also noted that the rate of decay in those under 4 m of age
in the total sample (where maternal antibodies are highest and
least likely to be inﬂuenced by transmission) was  relatively high
(−0.64 log2PRNT/month). Thus, we conclude that the rate of decay
of RSV speciﬁc maternal neutralising antibodies is between −0.58
and −0.67 log2PRNT titres per month, i.e. with average half-life of
36–31 days.
The level of speciﬁc RSV neutralising antibody required to pre-
vent disease is not precisely known, but indirect estimates of a
protective threshold are reported as 6 and 7.5 log2PRNT [10,20].
Our study suggests the vast majority of individuals to be born
with titres above this threshold, and furthermore, that over 50%
of individuals remain so for around 5–6 m.  The indication is that
raising levels of cord RSV antibody by maternal vaccination above
the median level identiﬁed in this study would provide protec-
tion to most infants over the ﬁrst 5–6 m of life deemed to be the
most critical for life-threatening RSV disease. Clearly, more work
is required to estimate directly the level of protective neutralising
antibodies.
Our ﬁndings also indicate that the rate of decay of maternally
derived neutralising antibodies is independent of starting (cord)
level. This result is of signiﬁcance since it suggests a constant
increase in beneﬁt from boosting titres, i.e. for each doubling rise
in antibody an increase in duration above a putative protective
threshold of around 50 days. This means, a theoretical RSV vac-
cine which increases maternal antibody titres by approximately 4
fold, would shift the age frequency curve of RSV disease to the right
by about 100 days. The above assertion assumes that cord RSV anti-
body boosted by a maternal vaccine would decay at the same rate
as cord antibody of the same level passively transferred from the
mother in the absence of vaccination.
Furthermore, although based on a small sample size, we ﬁnd
some evidence for an inverse relationship between population
level neutralising antibody titres (inferred from cord sera) and
population level virus transmission. RSV speciﬁc neutralising anti-
bodies decline in the absence of exposure and increase following
an increase in virus transmission at population level. As suggested
by Stensballe, this implies that a decline in herd immunity may
establish the conditions necessary for the spread of the virus [20].
Our study has a number of limitations. The results are appropri-
ate to a single rural developing country population. Future studies
would be of use to provide comparative data in sub-Saharan Africa,
in the Indian sub-continent, and in both urban and rural popu-
lations. The level and duration of maternal antibody may  also
vary according to concurrent maternal infections such as HIV and
malaria, which are all important factors which this study was not
designed to investigate. Measurement error in determining ges-
tational age and hence the pravelence of prematurity could be
addressed in future studies through use of standard ultrasound
procedures. RSV infects very early in life and the inﬂuence of trans-
mission on the estimated rate of decay is problematic. We  have
taken steps to remove the effect of RSV infection on estimating
the rates of decay and determined a realistic range within which
the real rate lies. However, there remains the possibility that early
infections in the presence of moderate to high titre maternal anti-
body might not have been detected. Analysis of cord level in relation
to prevalent RSV group within a population has not been under-
taken. Finally, neutralisation assays are frequently based on RSV A2
virus (without comparison with other strains or alternative group)
and not standardised between laboratories and this complicates
comparison of results between studies in different locations.
5. Conclusions
The results of this study provide precise estimates of the level
and duration of maternal RSV neutralisation antibody transfer for
a rural developing country population. Similar studies are required
in a range of settings. Interpretation of these results requires better
understanding of the relationship between the level of RSV-speciﬁc
neutralising antibody and protection from infection and disease,
and the capability of maternal vaccines to boost speciﬁc RSV pro-
tective antibodies in relation to existing antibody levels.
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